Gets FDA Orphan Drug Designation for AML Treatment
ImCheck Therapeutics’ lead candidate, ICT01, has received FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML)....
Strong Clinical Trial Results for Urcosimod
OKYO Pharma’s Phase 2 trial of urcosimod for neuropathic corneal pain (NCP) yielded positive top-line results. The trial involved...
CUE-101 & Pembro Show Promising 50% Response in HPV+ Head & Neck Cancer Trial
Cue Biopharma announced positive clinical updates for CUE-101, its lead drug candidate for recurrent/metastatic head and neck squamous cell...
Zervimesine Shows Promise in Dementia with Lewy Bodies
Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s...
Voyager Adds Fourth Alzheimer’s Program to Pipeline
Voyager Therapeutics has expanded its Alzheimer’s disease pipeline with a new gene therapy program targeting APOE, the strongest genetic...
Sellas’ SLS009 Shows Promise in AML Phase 2 Trial, FDA Guides First-Line Study
SELLAS Life Sciences‘ Phase 2 trial of SLS009 (tambiciclib), a CDK9 inhibitor, for relapsed/refractory acute myeloid leukemia (r/r AML)...
Positive Phase 3 Obesity Trial Results for HRS9531 in China
Hengrui Pharma and Kailera Therapeutics announced positive topline data from a Phase 3 clinical trial of HRS9531/KAI-9531, a novel...
Mayo Clinic Joins Briacell’s Phase 3 Metastatic Breast Cancer Study
BriaCell Therapeutics has added Mayo Clinic as a clinical site for its ongoing Phase 3 clinical trial for Bria-IMT™,...
ProKidney and FDA Align on Rilparencel Accelerated Approval
ProKidney Corporation announced that the FDA has confirmed eGFR slope as an acceptable surrogate endpoint for the accelerated approval...
AAVB-039 FDA Clearance for Stargardt Disease Celeste Trial
AAVantgarde Bio received FDA clearance for its Investigational New Drug (IND) application for AAVB-039, a gene therapy for Stargardt...